ArticleTurkish journal of physical medicine and rehabilitation2025
Effects of ozone and methylprednisolone treatment in facial paralysis: An experimental study.
Article in Turkish journal of physical medicine and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to compare ozone with the commonly used methylprednisolone in experimental facial paralysis and to investigate whether combining ozone with methylprednisolone provides additional benefits over methylprednisolone alone. Materials and methods: The prospective randomized controlled animal study was conducted between November 2023 and January 2024. Thirty-two male Sprague-Dawley rats (mean weight: 300±30 g; range, 270 to 330 g; mean age: 8±1 weeks) with experimentally induced facial nerve injury were divided into five subgroups: control, paralyzed, methylprednisolone (2 mg/kg/day, intramuscular), ozone (1.1 mg/kg/day, intraperitoneal), and combination (ozone+methylprednisolone). Treatments were administered for 14 days. Functional, histologic, and immunohistochemical examinations were made. Results: Posttreatment comparison of treatment groups showed that whisker movements (p=0.001) and total clinic scores (p=0.023) were significantly higher in the combination group compared to the ozone group. In histologic analysis, vascular congestion was significantly lower in the methylprednisolone group than in the ozone group (p=0.012). On the other hand, apoptosis levels, indicating cell death in the facial nerve, were significantly lower in the combination group compared to the methylprednisolone (p=0.016) and ozone (p=0.036) groups. Conclusion: The combination of methylprednisolone and ozone lead to the most favorable functional and cellular outcomes. Further studies are required to confirm the benefits of ozone therapy for human facial paralysis, understand the molecular mechanisms behind its effectiveness, and determine the optimal doses for combined treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.